|
|
|
|
||
Hold
Observations/ThursdayIt is curious, isn't it, that ALPMY did not get, even a small pop, in stock price, with the announcement of its dermatology division, for cash equivalent to twice the purchase price of OCAT. Heck, they can replenish what they spent, and have funding money for one or more OCAT clinical trials. Comments anyone? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
6 | Re: Observations/Thursday | tekbull | 0 | 11/12/2015 12:54:16 PM |